Naviscan

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Manoa Medical develops an advanced method of diagnosis and treatment of breast cancer.

Halo Healthcare, formerly NeoMatrix, develops devices that allow women and doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test, is a fully automated, non-invasive breast cancer risk assessment device designed for use in the primary care setting as part of an annual well-woman visit. The HALO Breast Pap Test is FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.

Seno Medical is a medical imaging company. It develops and markets optoacoustic imaging technology for cancer diagnosis. It offers Imagio, a breast imaging system that combines laser optics and ultrasound technology to provide fused functional and anatomical breast imaging in real-time. It was founded in 2005 and is based in San Antonio, Texas.

Micrima develops a system to improve the detection of breast cancer. The imaging system captures three-dimensional (3D) images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms. It was founded in 2006 and is based in Bristol, United Kingdom.

National P.E.T. Scan is a provider of diagnostic imaging services with four freestanding outpatient positron emission tomography/computerized tomography ("PET-CT") facilities in Florida.